Boceprevir for Chronic Genotype 1 Hepatitis C Virus in the Current Health Care Setting in Greece: A Cost-effectiveness Analysis

Clinical Therapeutics

Volumn 37, Issue 7, 2015, Pages 1529-1540

  Athanasakis, Kostas ^a   Ferrante, Shannon Allen ^b   Kyriopoulos, Ilias Ioannis ^a   Petrakis, Ioannis ^a   Hill, Mary ^c   Retsa, Maria Pagona ^c   Kyriopoulos, John ^a  

^a NATIONAL SCHOOL OF PUBLIC HEALTH   (Greece)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MSD Hellas   (Greece)

Author keywords

Boceprevir; chronic hepatitis C; cost effectiveness; genotype 1; pegylated interferon; ribavirin

Indexed keywords

BOCEPREVIR; PEGINTERFERON; RIBAVIRIN; ALPHA INTERFERON; ANTIVIRUS AGENT; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; PEGINTERFERON ALPHA2B; PROLINE; RECOMBINANT PROTEIN;

ARTICLE; CHRONIC HEPATITIS C; COMPARATIVE STUDY; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DECOMPENSATED LIVER CIRRHOSIS; DRUG COST; GREECE; HEALTH CARE; HEPATITIS C VIRUS GENOTYPE 1; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); QUALITY ADJUSTED LIFE YEAR; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; COMBINATION DRUG THERAPY; COST BENEFIT ANALYSIS; DISEASE COURSE; ECONOMICS; EPIDEMIOLOGY; GENETICS; GENOTYPE; HEALTH CARE COST; HEPACIVIRUS; HEPATITIS C, CHRONIC; LIFE EXPECTANCY; MARKOV CHAIN; MORTALITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; VIROLOGY;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE PROGRESSION; DRUG COSTS; DRUG THERAPY, COMBINATION; GENOTYPE; GREECE; HEALTH CARE COSTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LIFE EXPECTANCY; MARKOV CHAINS; MODELS, ECONOMETRIC; POLYETHYLENE GLYCOLS; PROLINE; QUALITY-ADJUSTED LIFE YEARS; RECOMBINANT PROTEINS; RIBAVIRIN; SENSITIVITY AND SPECIFICITY;

EID: 84937632222     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2015.05.003     Document Type: Article

References (47)

1. European Association for the Study of the Liver: EASL Clinical Practice Guidelines: Management of hepatitis C virus infection J Hepatol 60 2014 392 420
2. T. Poynard, P. Bedossa, and P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups Lancet 349 1997 825 832
3. World Health Organization. WHO Hepatitis C Factsheet. http://www.who.int/mediacentre/factsheets/fs164/en/index.html. Accessed June 7, 2014
4. M. Raptopoulou, G. Touloumi, D. Tzourmakliotis, and et al. Significant epidemiological changes in chronic hepatitis C infection: results of the nationwide HEPNET-GREECE cohort study Hippokratia 15 2011 26 31
5. M. Solomon, M. Bonafede, K. Pan, and et al. Direct medical care costs among pegylated interferon plus ribavirin treated and untreated chronic hepatitis C patients Dig Dis Sci 56 2011 3024 3031
6. K. Athanasakis, D. Arzoumanidou, I. Petrakis, and et al. A cost-of-illness analysis of hepatitis C in Greece Value Health 16 2013 A496
7. E.H. Elbasha, J. Chhatwal, S.A. Ferrante, and et al. Cost-effectiveness analysis of boceprevir for the treatment of chronic hepatitis c virus genotype 1 infection in Portugal Appl Health Econ Health Policy 11 2013 65 78
8. Merck Sharp & Dohme. Victrelis (boceprevir) [prescribing information]. [ http://www.merck.com/product/usa/pi-circulars/v/victrelis/victrelis-pi.pdf ]. Accessed June 6, 2014
9. F. Poordad, J. McCone Jr, B.R. Bacon, and et al. SPRINT-2 Investigators: Boceprevir for untreated chronic HCV genotype 1 infection N Engl J Med 364 2011 1195 1206
10. B.R. Bacon, S.C. Gordon, E. Lawitz, and et al. HCV RESPOND-2 Investigators: Boceprevir for previously treated chronic HCV genotype 1 infection N Engl J Med 364 2011 1207 1217
11. H.H. Thein, Q. Yi, G.J. Dore, and M.D. Krahn Estimation of stage specific fibrosis progression rates in chronic hepatitis C virus infection: A meta analysis and meta regression Hepatology 48 2008 418 431
12. G. Fattovich, G. Giustina, F. Degos, and et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients Gastroenterology 112 1997 463 472
13. L. Benvegnu, F. Noventa, E. Bernardinello, and et al. Evidence for an association between aetiology of cirrhosis and pattern of hepatocellular carcinoma development Gut 48 2001 110 115
14. P. Gentilini, G. Laffi, G. La Villa, and et al. Long course and prognostic factors of virus-induced cirrhosis of the liver Am J Gastroenterol 92 1997 66 72
15. A. Sangiovanni, G.M. Prati, P. Fasani, and et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17 year cohort study of 214 patients Hepatology 43 2006 1303 1310
16. L. Serfaty, H. Aumaitre, O. Chazouilleres, and et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis Hepatology 27 1998 1435 1440
17. S. Bruno, E. Silini, A. Crosignani, and et al. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study Hepatology 25 1997 754 758
18. H. Tsukuma, T. Hiyama, S. Tanaka, and et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease N Engl J Med 328 1993 1797 1801
19. M. Tateyama, H. Yatsuhashi, N. Taura, and et al. Alpha-fetoprotein above normal levels as a risk factor for the development of hepatocellular carcinoma in patients infected with hepatitis C virus J Gastroenterol 46 2011 92 100
20. H. Yoshida, Y. Shiratori, M. Moriyama, and et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan Ann Intern Med 131 1999 174 181
21. R. Planas, B. Ballesté, M.A. Alvarez, and et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients J Hepatol 40 2004 823 830
22. G.L. Davis, M.J. Alter, H. El-Seraq, and et al. Aging of hepatitis C virus (HCV)-infected persons in the United States: A multiple cohort model of HCV prevalence and disease progression Gastroenterology 138 2010 513 521
23. P.J. Thuluvath, M.K. Guidinger, J.J. Fung, and et al. Liver transplantation in the United States, 1999-2008 Am J Transplant 10 2010 1003 1019
24. K. Lang, N. Danchenko, K. Gondek, and et al. The burden of illness associated with hepatocellular carcinoma in the United States J Hepatol 50 2009 89 99
25. S. Saab, D.R. Hunt, M.A. Stone, and et al. Timing of hepatitis C antiviral therapy in patients with advanced liver disease: A decision analysis model Liver Transpl 16 2010 748 759
26. A.C. Cardoso, R. Moucari, C. Figueiredo-Mendes, and et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis J Hepatol 52 2010 652 657
27. World Health Organization. Global Health Observatory Data Repository, 2009 Life Tables for Greece. [ http://apps.who.int/gho/data/?theme=main ]. Accessed April 3, 2014
28. R.A. Wolfe, E.C. Roys, and R.M. Merion Trends in organ donation and transplantation in the United States, 1999-2008 Am J Transplant 10 2010 961 972
29. U. Siebert, G. Sroczynski, S. Rossol, and et al. German Hepatitis C Model (GEHMO) Group; International Hepatitis Interventional Therapy (IHIT) Group: Cost effectiveness of peginterferon-2b plus ribavirin versus interferon-2b plus ribavirin for initial treatment of chronic hepatitis C Gut 52 2003 425 432
30. M. Wright, R. Grieve, J. Roberts, and et al. UK Mild Hepatitis C Trial Investigators: Health benefits of antiviral therapy for mild chronic hepatitis C: Randomized controlled trial and economic evaluation Health Technol Assess 10 2006 1 113
31. J. Wilson, G.L. Yao, J. Raftery, and et al. A systematic review and economic evaluation of epoetin alfa, epoetin beta and darbepoetin alfa in anaemia associated with cancer, especially that attributable to cancer treatment Health Technol Assess 11 2007 1 202
32. C.A. Chong, A. Gulamhussein, E.J. Heathcote, and et al. Health-state utilities and quality of life in hepatitis C patients Am J Gastroenterol 98 2003 630 638
33. Prices for Pharmaceuticals. [ http://www.moh.gov.gr/articles/times-farmakwn/deltia-timwn ].
34. A.H. Briggs, A.E. Ades, and M.J. Price Probabilistic sensitivity analysis for decision trees with multiple branches: use of the Dirichlet distribution in a Bayesian framework Med Decis Making 23 2003 341 350
35. S.A. Ferrante, J. Chhatwal, C.A. Brass, and et al. Boceprevir for previously untreated patients with chronic hepatitis C genotype 1 infection: A US-based cost-effectiveness modeling study BMC Infect Dis 13 2013 190
36. J. Chhatwal, S.A. Ferrante, C. Brass, and et al. Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States Value Health 16 2013 973 986
37. A. Blázquez-Pérez, R. San Miguel, and J. Mar Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients Pharmacoeconomics 31 2013 919 931
38. C. Cammà, S. Petta, G. Cabibbo WEF Study Group Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C J Hepatol 59 2013 658 666
39. C. Cammà, S. Petta, M. Enea WEF Study Group Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C Hepatology 56 2012 850 860
40. P.A. Cortesi, A. Ciaccio, M. Rota, and et al. Management of treatment-naïve chronic hepatitis C genotype 1 patients: A cost-effectiveness analysis of treatment options J Viral Hepat 22 2015 173 181
41. M.H. Wehmeyer, F. Eissing, S. Jordan, and et al. Safety and efficacy of protease inhibitor based combination therapy in a single-center "real-life" cohort of 110 patients with chronic hepatitis C genotype 1 infection BMC Gastroenterol 14 2014 87
42. S.C. Gordon, A.J. Muir, J.K. Lim, and et al. Safety profile of boceprevir and telaprevir in chronic hepatitis C: Real world experience from HCV-TARGET J Hepatol 62 2015 286 293
43. D.A. Revicki, and L. Frank Pharmacoeconomic evaluation in the real world PharmacoEconomics 15 1999 423 434
44. E.R. Feeney, and R.T. Chung Antiviral treatment of hepatitis C BMJ 348 2014 g3308
45. European Association for the Study of the Liver. EASL Recommendations on Treatment of Hepatitis C 2014. [ http://files.easl.eu/easl-recommendations-on-treatment-of-hepatitis-C.pdf ]. Accessed September 9, 2014
46. American Association for the Study of Liver Diseases. Recommendations for Testing, Managing, and Treating Hepatitis C. [ http://www.hcvguidelines.org/full-report-view ]. Accessed September 9, 2014
47. K.L. Davis, D. Mitra, and J. Medjedovic Direct economic burden of chronic hepatitis C virus in a United States managed care population J Clin Gastroenterol 45 2011 17 24